Capital Impact Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Capital Impact Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-15,923	Closed	-$2.38M	–	112
2019 Q4	$2.38M	Buy	+15,923	New	+$2.17M	0.84%	36
2019 Q3	–	Sell	-7,699	Closed	-$1.06M	–	125
2019 Q2	$1.06M	Hold	7,699	–	–	0.39%	117
2019 Q1	$937K	Hold	7,699	–	–	0.42%	119
2018 Q4	$937K	Hold	7,699	–	–	0.4%	123
2018 Q3	$1.28M	Hold	7,699	–	–	0.44%	115
2018 Q2	$1.34M	Hold	7,699	–	–	0.5%	115
2018 Q1	$1.16M	Buy	7,699 +2,045	+36%	+$300K	0.48%	116
2017 Q4	$761K	Hold	5,654	–	–	0.33%	136
2017 Q3	$827K	Sell	5,654 -3,528	-38%	-$534K	0.37%	138
2017 Q2	$1.43M	Hold	9,182	–	–	0.65%	58
2017 Q1	$1.33M	Buy	9,182 +3,456	+60%	+$450K	0.53%	104
2016 Q4	$624K	Hold	5,726	–	–	0.26%	190
2016 Q3	$696K	Hold	5,726	–	–	0.3%	185
2016 Q2	$809K	Sell	5,726 -12,105	-68%	-$1.78M	0.38%	153
2016 Q1	$2.33M	Buy	17,831 +5,031	+39%	+$626K	1.11%	2
2015 Q4	$1.8M	Buy	+12,800	New	+$1.77M	0.86%	13
2014 Q2	–	Sell	-14,262	Closed	-$1.98M	–	224
2014 Q1	$1.98M	Hold	14,262	–	–	1.59%	4
2013 Q4	$1.8M	Buy	+14,262	New	+$1.48M	1.45%	7

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Capital Impact Advisors's JAZZ Position: Q1 2020 in Review

Capital Impact Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2020, closing a stake of 15,923 shares — an estimated $2.38M sold.

Capital Impact Advisors first reported a position in JAZZ in Q4 2013 and held it in 18 quarters. The position peaked at $2.38M in Q4 2019. 407 funds tracked by Wall St. Rank hold JAZZ as of Q1 2020.

Capital Impact Advisors reported no remaining Jazz Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Capital Impact Advisors sold 15,923 Jazz Pharmaceuticals shares in Q1 2020, an estimated $2.38M.
Capital Impact Advisors first reported a position in Jazz Pharmaceuticals in Q4 2013 and held it in 18 quarters.
Capital Impact Advisors's Jazz Pharmaceuticals position peaked at $2.38M in Q4 2019.
407 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2020.

Based on Capital Impact Advisors's 13F filing for Q1 2020, filed 15 May 2020.